Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin; Says 'While There Was a Favorable Trend for Incidence of Varices in the Primary End Point Intent-to-treat Population, Belapectin Did Not Achieve...

Galectin Therapeutics宣佈NAVIGATE臨牀試驗評估Belapectin的頂線結果；表示『儘管在意向治療人群的主要終點方面存在有利趨勢，但Belapectin未能達到...』

Benzinga · 12/20 21:03

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin; Says 'While There Was a Favorable Trend for Incidence of Varices in the Primary End Point Intent-to-treat Population, Belapectin Did Not Achieve Statistical Significance'

Galectin Therapeutics 宣佈了評估 Belapectin 的 NAVIGATE 臨牀試驗的初步結果；表示「儘管在主要終點意向治療人群中，靜脈曲張發生率有利趨勢，但 Belapectin 並未達到統計學意義。」

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。